Abstract: Objective To investigate the efficacy and toxicity of the modified TCD regimen(low-dose thalidomide and dexamethasone in combination with cyclophosphamide）for the treatment of newly diagnosed multiple myeloma. Methods All patients were treated with the modified TCD regimen for 6 courses.Serum protein electrophoresis(M protein and quantity)，immunofixation electrophoresis，bone marrow cell morphology and β2-microglobulin were applied to access the treatment efficacy.The adverse events were also observed. Results When treatments were completed，6 cases achieved complete remission (CR)，7 cases achieved nearly complete remission(nCR)，5 cases achieved partial remission(PR)，2 cases achieved minimal response.Overall remission rate was 69.2%，overall response rate was 76.9%.Toxical and side effect was minimal.No treatment related mortality was observed. Conclusion The modified TCD regimen is a safe and effective regimen which can be used in treatment of patients with newly diagnosed multiple myeloma and worthy for clinical use.